{"filing":{"accession_number":"0001213900-26-073097","cik":"0001893645","ticker":"PLRZ","company_name":"Polyrizon Ltd.","form":"6-K","filing_date":"2026-06-29","report_date":null,"primary_document":"ea0296243-6k_polyrizon.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1893645/000121390026073097/ea0296243-6k_polyrizon.htm"},"events":[{"id":14589,"run_id":12998,"accession_number":"0001213900-26-073097","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Polyrizon announced receipt of central IRB approval from BRANY to begin its first human clinical trial for NASARIX™, an intranasal hydrogel allergy blocker. This is a material regulatory milestone for a development-stage biotech company—it represents significant progress toward commercialization of a lead product candidate and enables advancement to site activation and patient enrollment. While not fitting a discrete named event type, this is clearly an operational/strategic milestone that would affect a reasonable investor's assessment of the company's development trajectory and near-term prospects.","company_name":"Polyrizon Ltd.","ticker":"PLRZ","filing_date":"2026-06-29","form":"6-K","submitted_at":null,"items":[{"id":12067,"accession_number":"0001213900-26-073097","item_number":"EX-99.1","item_title":"ea029624301ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Polyrizon announced receipt of central IRB approval from BRANY to begin its first human clinical trial for NASARIX™, an intranasal hydrogel allergy blocker. This is a material regulatory milestone for a development-stage biotech company—it represents significant progress toward commercialization of a lead product candidate and enables advancement to site activation and patient enrollment. While not fitting a discrete named event type, this is clearly an operational/strategic milestone that would affect a reasonable investor's assessment of the company's development trajectory and near-term prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:03:41.215494+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12067,"accession_number":"0001213900-26-073097","item_number":"EX-99.1","item_title":"ea029624301ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Polyrizon announced receipt of central IRB approval from BRANY to begin its first human clinical trial for NASARIX™, an intranasal hydrogel allergy blocker. This is a material regulatory milestone for a development-stage biotech company—it represents significant progress toward commercialization of a lead product candidate and enables advancement to site activation and patient enrollment. While not fitting a discrete named event type, this is clearly an operational/strategic milestone that would affect a reasonable investor's assessment of the company's development trajectory and near-term prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:03:41.215494+00:00","company_name":"Polyrizon Ltd.","ticker":"PLRZ","filing_date":"2026-06-29"}]}